Related Experiment Video
Updated: Apr 28, 2026

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
Current good manufacturing practices, quality control procedures, quality factors, notification requirements, and
Abstract:
The Food and Drug Administration (FDA or we) is issuing a final rule that adopts, with some modifications, the interim final rule (IFR) entitled "Current Good Manufacturing Practices, Quality Control Procedures, Quality Factors, Notification Requirements, and Records and Reports, for Infant Formula'' (February 10, 2014). This final rule affirms the IFR's changes to FDA's regulations and provides additional modifications and clarifications. The final rule also responds to certain comments submitted in response to the request for comments in the IFR.
More Related Videos
04:16Individualized Reconstitution of Human Milk Microbiota: A Feasible Approach in Real-World Settings
Published on: February 7, 2025
09:37A cGMP-applicable Expansion Method for Aggregates of Human Neural Stem and Progenitor Cells Derived From Pluripotent Stem Cells or Fetal Brain Tissue
Published on: June 15, 2014
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Clinically Relevant Drug Product Specifications: Methods of Establishment
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Drug Regulation
Drug Dosing: Infants and Children
Production of Pharmaceuticals